POLE and colorectal carcinoma: The overall mutation rate of SYNE1 in TCGA CRC cohort (excluding MSI and POLE‐mutated samples) was 18%, with patients harboring SYNE1 mutations exhibiting poorer overall survival (Log‐rank p = 0.0427).